Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566525 · ClinicalTrials.gov registry record · NA
CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery
A NA study of Elective Cardiac Surgery, sponsored by CytoSorbents.
- Completed
- Registry status
- NA
- Development phase
- 52
- Enrollment target
- 8
- Study locations
NCT02566525 is a NA study of Elective Cardiac Surgery that has completed, run by CytoSorbents. The registered enrollment target is 52 participants. The trial reports 8 study locations across 7 states.
The verdict
NCT02566525, a NA study of Elective Cardiac Surgery, has completed, sponsored by CytoSorbents.
- COMPLETED
- Registry status
- NA
- Development phase
- 52 participants
- Enrollment target
- 8
- Study locations
Study Summary
Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.
Conditions Studied
Interventions
- DEVICE CytoSorb
Study Locations (8)
Pennsylvania
- University of Pennsylvania - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Kentucky
- University of Kentucky - Lexington
Maryland
- University of Maryland - Baltimore
Massachusetts
- Baystate Medical - Springfield
New Jersey
- Cooper University Hospital - Camden
New York
- Columbia University - New York
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02566525
The ClinicalTrials.gov registry entry for NCT02566525 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytoSorbents, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Elective Cardiac Surgery appearing as the primary indexed condition, and to 1 intervention - of which CytoSorb is the first listed.
NCT02566525 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Pennsylvania, Kentucky, Maryland.
Frequently Asked Questions
What is clinical trial NCT02566525 about?
NCT02566525 is a clinical study titled "CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery". Prospective, multi-center, randomized, feasibility clinical study. Subjects will be randomized in a 1:1 ratio to either standard of care (SOC) alone or standard of care and treatment with the CytoSorb® device.
What is the current status of trial NCT02566525?
This trial is currently completed. It is a NA study. The enrollment target is 52 participants. The study started on 2015-11. Estimated completion is 2016-12.
What conditions does trial NCT02566525 study?
This clinical trial studies the following conditions: Elective Cardiac Surgery.
What interventions are being tested in trial NCT02566525?
The interventions under investigation include: CytoSorb (DEVICE).
Who is sponsoring clinical trial NCT02566525?
This trial is sponsored by CytoSorbents, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02566525 being conducted?
This trial has 8 study locations across Kentucky, Maryland, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.